Table 3.
Regression analysis of the OCI-CV scale t1 scores on the OBQ-CV and CDI t0 scores (n = 754)
| Outcome: OCI-CV Ordering at t1 | β | t | p value | R2 change | R2 |
|---|---|---|---|---|---|
| OBQ-CV Perfectionism/Intolerance of Uncertainty at t0 | 0.19 | 4.69 | < 0.001 | 0.08 | |
| CDI Total at t0 | 0.13 | 3.66 | < 0.001 | 0.02 | 0.11 |
| OBQ-CV Threat Overestimation at t0 | 0.13 | 3.31 | < 0.001 | 0.01 | |
| Outcome: OCI-CV Washing at t1 | β | t | p value | R2 change | R2 |
| OBQ-CV Threat Overestimation at t0 | 0.19 | 4.74 | < 0.001 | 0.08 | 0.10 |
| OBQ-CV Perfectionism/Intolerance of Uncertainty at t0 | 0.17 | 0.18 | < 0.001 | 0.02 | |
| Outcome: OCI-CV Doubting/Checking at t1 | β | t | p value | R2 change | R2 |
| OBQ-CV Perfectionism/Intolerance of Uncertainty at t0 | 0.21 | 5.63 | < 0.001 | 0.16 | |
| CDI Total at t0 | 0.22 | 6.98 | < 0.001 | 0.07 | 0.25 |
| OBQ-CV Threat Overestimation at t0 | 0.17 | 4.28 | < 0.001 | 0.03 | |
| OBQ-CV Importance/Control of Thoughts at t0 | 0.09 | 2.62 | < 0.01 | 0.01 | |
| Outcome: OCI-CV Neutralising at t1 | β | t | p value | R2 change | R2 |
| OBQ-CV Threat Overestimation at t0 | 0.21 | 4.93 | < 0.001 | 0.08 | |
| CDI Total at t0 | 0.18 | 5.35 | < 0.001 | 0.04 | 0.14 |
| OBQ-CV Perfectionism/Intolerance of Uncertainty at t0 | 0.14 | 3.67 | < 0.001 | 0.01 | |
| OBQ-CV Inflated Responsibility at t0 | 0.09 | 2.50 | < 0.05 | 0.01 | |
| Outcome: OCI-CV Hoarding at t1 | β | t | p value | R2 change | R2 |
| CDI Total at t0 | 0.17 | 4.76 | < 0.001 | 0.04 | |
| OBQ-CV Importance/Control of Thoughts at t0 | 0.10 | 2.74 | < 0.001 | 0.02 | 0.06 |
| OBQ-CV Inflated Responsibility at t0 | 0.09 | 2.41 | < 0.05 | 0.01 | |
| Outcome: OCI-CV Pure obsessing at t1 | β | t | p value | R2 change | R2 |
| CDI Total at t0 | 0.26 | 7.53 | < 0.001 | 0.10 | 0.16 |
| OBQ-CV Threat Overestimation at t0 | 0.24 | 7.17 | < 0.001 | 0.06 |
Note. CDI = Children Depression Inventory, OBQ-CV = Obsessive Belief Questionnaire-Child Version, OCI-CV = Obsessive Compulsive Inventory-Child Version. t0 = baseline, t1 = one-year follow-up.